This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

IK-2001

Mallinckrodt plc

Drug Names(s): Inhaled carbon monoxide (iCO), Covox

Description: IK-2001 is inhaled carbon monoxide (iCO), an endogenous (naturally produced by the body) mediator of a number of biologic processes.

Deal Structure: Mallinckrodt and Ikaria
In March 2015, Mallinckrodt announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Ikaria in a transaction valued at approximately $2.3 billion.

In April 2015, Mallinckrodt completed its acquisition of Ikaria at a purchase price of approximately $2.3 billion. The all-cash transaction is expected to add at least $150 million in net sales and be accretive to the company's fiscal year 2015 adjusted diluted earnings per share by at least $0.25 per share.


IK-2001 News

Pink Sheet Advanced Therapies


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug